Literature DB >> 12427361

Update on the treatment of Kawasaki disease in childhood.

Robert P Sundel1.   

Abstract

Intravenous immunoglobulin (IVIG) treatment for Kawasaki disease (KD), first discovered almost 20 years ago, dramatically changed the management and prognosis of the condition. Although standard Japanese Ministry of Health criteria suggest that current treatment is more than 95% effective at preventing coronary artery changes, echocardiographic measurements adjusted for body size, imply a far higher incidence of coronary artery dilitation despite prompt therapy. If one also considers data on chronic alterations in endothelial function after KD, then more effective approaches to the management of acute and recurrent KD are needed. A variety of possible adjunct therapies--most notably high-dose corticosteroids--currently are being studied to determine whether better long-term outcomes may be achieved than with IVIG alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427361     DOI: 10.1007/s11926-002-0053-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  51 in total

1.  Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin.

Authors:  A M Moran; J W Newburger; S P Sanders; I A Parness; P J Spevak; J C Burns; S D Colan
Journal:  Am Heart J       Date:  2000-02       Impact factor: 4.749

2.  [Two infants with classical polyarteritis nodosa but not Kawasaki disease].

Authors:  T Miyamae; S Nakasima; N Tomono; M Mori; M Ibe; K Yasui; S Yokota; T Mori
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  2000-10

3.  [Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins].

Authors:  E Villain; J Kachaner; D Sidi; G Blaysat; J F Piéchaud; E Pedroni
Journal:  Arch Fr Pediatr       Date:  1987-02

4.  Antioxidants may mitigate the deterioration of coronary arteritis in patients with Kawasaki disease unresponsive to high-dose intravenous gamma-globulin.

Authors:  C T Shen; N K Wang
Journal:  Pediatr Cardiol       Date:  2001 Sep-Oct       Impact factor: 1.655

5.  Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities.

Authors:  M Marasini; G Pongiglione; D Gazzolo; A Campelli; D Ribaldone; S Caponnetto
Journal:  Am J Cardiol       Date:  1991-09-15       Impact factor: 2.778

6.  Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?

Authors:  Richard V Williams; Venus M Wilke; Lloyd Y Tani; L LuAnn Minich
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

7.  Kawasaki disease in infants less than one year of age.

Authors:  E A Rosenfeld; K E Corydon; S T Shulman
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

8.  Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.

Authors:  S Furukawa; T Matsubara; Y Umezawa; T Motohashi; T Ino; K Yabuta
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

9.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

10.  The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.

Authors:  K Durongpisitkul; V J Gururaj; J M Park; C F Martin
Journal:  Pediatrics       Date:  1995-12       Impact factor: 7.124

View more
  2 in total

Review 1.  Pediatric vasculitis.

Authors:  Pamela F Weiss
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

2.  Increased α1-antitrypsin levels in acute-phase Kawasaki disease as shown by SELDI-TOF MS analysis.

Authors:  Takahiro Kanai; Hirohiko Shiraishi; Ritei Uehara; Takane Ito; Mariko Y Momoi
Journal:  Pediatr Cardiol       Date:  2012-05-12       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.